Abstract
Personalising cancer medicine depends upon the implementation of personalised diagnostics and therapeutics. Detailed genomic screening is likely to play a central role in this. As the range of drugs and other therapies for cancer continues to increase, there is an increasingly urgent need for sensitive and specific measures of disease burden to guide treatment regimens. The ability to quantify disease burden with high accuracy and sensitivity in patients with cancer would open many potential routes to personalising therapeutic choices. For example, the intensity of therapy could be guided by the amount of disease at diagnosis; monitoring the response of patients to drugs could allow extension of the period of treatment in responders or early changeover of therapy in nonresponders; and early prediction of recurrence could allow salvage therapy to be instituted before complications of relapse develop. The detection of tumour-specific rearrangements in DNA free in the serum or plasma may provide a substantial advance in the accuracy of monitoring disease burden in patients with solid tumours.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Branford S (2007) Chronic myeloid leukemia: molecular monitoring in clinical practice. Am Soc Hematol Educ Program 2007:376
Mandel P, Metais P (1948) Les acides nucleiques du plasma sanguin chez l′homme. CR Acad Sci Paris 142:241
Steinman CR (1975) Free DNA in serum and plasma from normal adults. J Clin Invest 56:512
Stroun M, Lyautey J, Lederrey C et al (2001) About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clinica chimica acta; J Clin Chem 313:139
Choi JJ, Reich CF 3rd, Pisetsky DS (2005) The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology 115:55
Jahr S, Hentze H, Englisch S et al (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61:1659
Diehl F, Li M, Dressman D et al (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 102:16368
Leon SA, Shapiro B, Sklaroff DM et al (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646
Fournie GJ, Courtin JP, Laval F et al (1995) Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 91:221
Diehl F, Schmidt K, Choti MA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985
Sorenson GD, Pribish DM, Valone FH et al (1994) Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomark Prev 3:67
Leary RJ, Kinde I, Diehl F et al (2010) Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2:20ra14
Esteller M, Sanchez-Cespedes M, Rosell R et al (1999) Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59:67
Wong IH, Lo YM, Zhang J et al (1999) Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 59:71
Grutzmann R, Molnar B, Pilarsky C et al (2008) Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PloS One 3:e3759
Margulies M, Egholm M, Altman WE et al (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature 437:376
Bentley DR, Balasubramanian S, Swerdlow HP et al (2008) Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456:53
McKernan KJ, Peckham HE, Costa GL et al (2009) Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding. Genome Res 19:1527
Campbell PJ, Stephens PJ, Pleasance ED et al (2008) Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 40:722
McBrid DJ, Orpana AK, Sotiriou C et al (2010) Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosom Cancer 49:1062
Umetani N, Giuliano AE, Hiramatsu SH et al (2006) Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 24:4270
Wang M, Block TM, Steel L et al (2004) Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA. Clin Chem 50:211
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Cooke, S., Campbell, P. (2012). Circulating DNA and Next-Generation Sequencing. In: Ignatiadis, M., Sotiriou, C., Pantel, K. (eds) Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. Recent Results in Cancer Research, vol 195. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-28160-0_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-28160-0_12
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-28159-4
Online ISBN: 978-3-642-28160-0
eBook Packages: MedicineMedicine (R0)